1 **Antibody response patterns to *Helicobacter pylori* infection in a rural Ugandan population** 2 **cohort.**

3
4 **Neneh Sallah^{1*}, Alexander Hayes^{1, a}, Nana Osei-Tutu^{1, a}, Julia Butt^{2*}, W. Thomas Johnston³,**
5 **Gershim Asiki⁴, Tim Waterboer^{2, §}, Martin L. Hibberd^{1, §}, Robert Newton^{3,5, §}.**

6 ¹London School of Hygiene & Tropical Medicine, London, U.K., ²Infections and Cancer
7 Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center
8 (DKFZ), Germany, ³Department of Health Sciences, University of York, U.K., ⁴African Population
9 and Health Research Centre, Kenya, ⁵MRC/UVRI at London School of Hygiene & Tropical
10 Medicine, Entebbe, Uganda

11 ^aAuthors contributed equally to this study

12 [§]Joint senior authors

13 *Authors for correspondence: Neneh Sallah, London School of Hygiene & Tropical Medicine, U.K
14 Neneh.Sallah@lshtm.ac.uk, & Julia Butt, Infections and Cancer Epidemiology, Infection,
15 Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Germany,
16 j.butt@dkfz.de

17
18 Keywords: *Helicobacter pylori*, antibody, bacteria, Africa, infection

19
20 Key Messages:

- 21 • Antibody responses to *H. pylori* antigens are found to be associated with risk of gastric cancer,
22 however, despite the high seroprevalence in African populations, data from Africa are scarce.
23 This is the first study of antibody response patterns and their determinants from an African
24 population.
- 25 • Our study shows a population where *H. pylori* is ubiquitous from childhood, and seroprevalence
26 of virulent antigens is distinctively high suggesting an increased of disease compared to other
27 populations.

- 28 • We observe inter-individual variation in virulent antibody responses partly influenced by co-
29 infection.
- 30 • We highlight crucial insights into antibody-based biomarkers of disease risk and reinforce the
31 need for population-based *H. pylori* screening and treatment programmes for gastric cancer
32 control.

33 Abstract word count: 248, Text word count: 2773

34

35 **Abstract**

36 Background: *Helicobacter pylori* (*H. pylori*) establishes life-long infection in humans in the absence
37 of treatment and has been associated with a variety of gastrointestinal conditions including peptic
38 ulcer and gastric cancer. Antibody responses to *H. pylori* antigens are found to be associated with
39 disease risk, however, data from Africa are scarce.

40 Methods: To assess the seroprevalence of *H. pylori* and characterise antibody response patterns, we
41 measured serum IgG antibody levels to 14 antigens among 7,211 individuals in a rural Ugandan
42 population cohort. Multivariate-adjusted linear regression models were fitted to investigate the
43 influence of age, sex, and co-infection on antibody seroreactivity levels.

44 Results: *H. pylori* seroprevalence was 95% in our study population, with 94% of individuals
45 seropositive in childhood (<15 years). In *H. pylori* positive individuals, we found a markedly high
46 seroprevalence (~99%) and antibody levels to the high-risk antigens CagA and VacA, in addition to
47 Cagδ. HSV-2 co-infection was significantly associated with higher IgG levels of CagA and VacA
48 (OR=1.10, 95% C. I.=1.05-1.16). HIV infection was associated with lowered IgG levels to CagA
49 (OR=0.86, 95% C.I.=0.80-0.93), and HPV infection was associated with increased IgG levels to
50 VacA (OR=1.16, 95% C.I.=1.11-1.21).

51 Conclusions: *H. pylori* in this population is ubiquitous from childhood, with a high prevalence and
52 high seroreactivity levels of high-risk antigens, suggesting chronic active inflammatory responses in
53 individuals that are indicative of risk of disease. Further investigation is warranted to fully understand

the relationship between host, immunogenicity, and clinical outcomes to better stratify by risk and improve treatment.

Introduction

Helicobacter pylori (*H. pylori*), is a gram-negative bacterium that colonises the gastric epithelium of the human host and is typically acquired in childhood via intrafamilial contact[1]. Globally, 4.4 billion individuals are estimated to be infected with *H. pylori* with substantial geographic variation in prevalence ranging from ~20-50% in developed countries to ~80% in developing countries[2]. While the majority of infections are asymptomatic, in the absence of treatment, *H. pylori* can evade the host's immune responses and subsequently persist throughout a person's lifetime. Chronic *H. pylori* infection is the strongest risk factor for several gastrointestinal conditions including, peptic ulcer, chronic atrophic gastritis, and gastric cancers worldwide[3]. In 2018, *H. pylori* was responsible for 810,000 (37%) new cases of cancers caused by an infectious agent and caused ~90% of non-cardia gastric cancers[3]. The relative risk of developing gastric cancer with the *H. pylori* infection is 17[4]. In sub-Saharan Africa, the estimated population attributable fraction (PAF) of non-cardia gastric cancer is 92%[4]. Between the 1960s and 2008, Uganda experienced a 7-fold increase in gastric cancer incidence[5]. In 2008, The Uganda Cancer Working Group recognised that in areas of endemic *H. pylori* infection, *H. pylori* predicated the multistage process that lead to the development of gastric cancer[5]. They recommended that *H. pylori* eradication be utilised as a prevention strategy in areas with a high incidence of gastric cancer[5]. This recommendation is shared by the International Agency for Research on Cancer (IARC) working group that population-based *H. pylori* screening and treatment programmes are needed for gastric cancer control[6].

While the understanding of potential disease outcome following *H.pylori* infection is limited, it is found to be mediated by the complex interplay between bacterial virulence factors, environmental factors, lower socioeconomic status and host factors[7]. During the course of infection, chronic inflammatory changes occur as the bacterium adapts to its host and modulates the immune system. Depending on the bacterium's protein expression pattern and the host's adaptive immune response

distinctive antibody response patterns may result and potentially reflect virulence of the infecting bacterium. As an example, antibody responses to particular *H. pylori* antigens: CagA (cytotoxin-associated antigen A), VacA (vacuolating cytotoxin), GroEL (chaperonin GroEL), HP1564 (hypothetical protein) and HcpC (conserved hypothetical secreted protein) have been identified as being associated with development of chronic atrophic gastritis and gastric cancers[8, 9]. A recent study characterised the dynamics of antibody responses to 15 antigens in a healthy German population-based cohort with a *H. pylori* seroprevalence of 48% and found multiple seropositivity and higher antibody levels associated with increasing age, suggestive of persistent infection and lifelong stimulation of immune responses[10]. Despite the high seroprevalence in African populations, there is a paucity of data, particularly from the continent compared to other populations[11, 12]. To better understand the relationship between host and pathogen in individuals the investigation of distinctive antibody patterns and factors that could potentially lead to disease following chronic infection is essential. Therefore, in this study, we assess the seroprevalence of *H. pylori* and antibody patterns against 14 antigens in a rural African population cohort and explore the factors associated with inter-individual variation in antibody response.

Methods

Sample selection and ethics

The General Population Cohort (GPC) is a population-based cohort in rural south-west Uganda consisting of 25 neighbouring villages inhabited mainly by farmers[13, 14]. The Baganda are the predominant tribal group constituting ~70% of the population, with a substantial number of migrants who settled from neighbouring Rwanda. Blood samples from 7,211 GPC study participants, representing 11 self-reported ethnolinguistic groups, were collected during census and medical survey sampling rounds conducted in the study area in 1992, 2000 and 2008, as described previously[13]. Serum was tested for infections and the remainder was stored at -80 degrees Celsius in freezers in Entebbe prior to further serological testing. Informed consent was obtained from all participants either in conjunction with parental/guardian consent for under 18-year olds with signature or a thumbprint if the individual was unable to write. The study was approved by the Uganda Virus Research Institutes,

Research Ethics committee (UVRI-REC) (Ref. GC/127/10/10/25), the Uganda National Council for Science and Technology (UNCST) and the London School of Hygiene & Tropical Medicine (LSHTM) Ethics Committee (reference number 17686).

Helicobacter pylori multiplex serology

We quantified mean fluorescent intensity (MFI) of IgG antibodies to 14 *H. pylori* antigens using multiplex serology on the Luminex® platform based on glutathione-S-transferase (GST) fusion capture immunosorbent assays combined with fluorescent bead technology as previously described[15]. The 14 recombinant affinity purified *H. pylori* proteins that were used as antigens were: CagA (cytotoxin-associated antigen A), GroEL (chaperonin GroEL), HP1564 (hypothetical protein HP1564), VacA (vacuolating cytotoxin), HP0231 (hypothetical protein HP0231), HP0305 (hypothetical protein HP0305), HpaA (neuraminyllactose-binding hemagglutinin homolog), Cagδ (cag pathogenicity island protein δ), HyuA (hydantoin utilization protein A), CagM (cag pathogenicity island protein M), Catalase, HcpC (conserved hypothetical secreted protein - paralogue HcpA induces IFNγ), NapA (neutrophil activating protein (bacterioferritin)) and UreA (urease alpha subunit). Antibody seropositivity was defined as reactivity greater than the antigen-specific cut-off. *H. pylori* seropositivity was defined as seropositivity to at least 4 antigens as described previously[10, 15].

Statistical analysis of variability in antibody responses

Statistical significance of differences in continuous variables, i.e. antibody reactivities (MFI values) and multiple seropositivity (number of antigens recognized) were analysed with the Wilcoxon two sample signed rank sum test. Fisher's Exact test was used to test for differences in dichotomous variables, i.e. *H. pylori* seropositivity and antibody seroprevalence. All tests were performed two-sided. Analyses were performed with R software version 3.4. P-values below 0.05 were considered statistically significant. Pairwise-correlation between antigens for seropositive individuals were tested using Spearman's rank-based test in R. We also investigated factors influencing IgG antibody response levels to *H. pylori* antigens. Antibody levels were log₁₀ transformed and multivariate linear

regression models were fitted to examine variables predictive of antibody levels. The variables tested were: sex, age/age group (categorized as 0-14, 15-24, 25-44 or ≥ 45 years), census (sampling) year (1992, 2000 or 2008) and infection status for Epstein-Barr virus (EBV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human-immunodeficiency virus (HIV), Human papillomavirus (HPV) high risk types 16 and 18, Herpes simplex virus type 2 (HSV-2), Human T-lymphotropic virus (HTLV-1), Kaposi's sarcoma-associated herpesvirus (KSHV), and Merkel cell polyomavirus (MCV). A multiple testing p -value of <0.005 adjusted for all variables was used to determine statistical significance unless specified otherwise.

Results

***Helicobacter pylori* seroprevalence in the GPC.**

In this study, we analysed the sera of 7,211 individuals between the ages of 0-98 years (median=16, IQR=10-35) for antibody responses to 14 different *H. pylori* antigens: CagA, GroEL, HP1564, VacA, HP0231, HP0305, HpaA, Cag δ , HyuA, CagM, Catalase, HcpC, NapA, and UreA. We categorised 95% of individuals as seropositive for *H. pylori* infection based on reactivity to at least 4 antigens (Table 1). While *H. pylori* seroprevalence was similar for both sexes (males 95.5% vs females 94%), we found that in the 25-44 years age group seroprevalence was significantly higher in males (97.3%) compared to females (94.9%) ($p=0.03$) (Figure 1). We also found that seroprevalence was significantly higher ($>2\%$) in the oldest age group (45+) compared to the youngest age group (0-14) for both males ($p=0.02$) and females ($p=0.01$) (Figure 1). Seroprevalence was also similarly high across census years (94-96%) (Table1). Seroreactivity to multiple antigens was high (median=8.7, IQR=7-11) with 3375 individuals (47%) testing seropositive for >9 antigens (Supplementary Figure 1.A). We found no significant differences in the number of antigens recognised across age groups or between sexes ($P>0.05$) (Supplementary Figure 1.B). We compared the seroprevalences of all antibodies to the 14 antigens in seropositive (HP+) vs seronegative (HP-) individuals and found that antibody seroprevalences were significantly higher in HP+ compared to HP- sera for all antigens ($p<0.0001$) (Table2). In the 6,834 *H. pylori* seropositive individuals, antibodies to CagA, VacA and

Cag δ were the highest with ~99% seroprevalence and antibodies to NapA and HcpC had the lowest seroprevalence being less than 50% (Table2).

Helicobacter pylori antibody response levels

Using the multiplex flow immunoassay, we quantified the antibody levels of response to the 14 different *H. pylori* antigens. In *H. pylori* positive and antigen-specific antibody positive individuals, we observed variation in antibody responses with the highest IgG levels observed for CagA (max=66,614, median=13,793, IQR=10,138-18,298) followed by VacA (max=28,722, median=2,809, IQR=1641-4600), HP1564 (max=22,526, median:2776, IQR=1341-4640) and Cag δ (max=15,044, median:2,206, IQR=1,293-3,609), all other antibody responses had medians below 2000 with HpaA having the lowest median IgG level (max= 10,783, median:335, IQR:182-751) (Figure 2.). There was a modest correlation between all antigens (ρ =-0.01-0.51) (Supplementary Figure S2), with the strongest correlation being observed for HP0305 and HP1564 (ρ =0.51) (Supplementary Figure S2).

We investigated the association between intrinsic factors, age, sex and sampling year to inter-individual variation in antibody response levels in seropositive individuals using a multivariable linear regression model for each antibody (Table 3). We found that higher age groups in comparison to the youngest age group (0-14) were significantly associated with decreased antibody levels to CagA, HP1564, VacA and HP0231 (ORs between 0.84-99) (Table 3). In contrast, higher age groups were significantly associated with increased antibody levels to GroEL, Cag δ , HyuA, NapA, HcpC and UreA (ORs between 1.01-1.21) in comparison to the youngest age group (Table 3). Being female was significantly associated (p <0.0125) with lower antibody responses to HP1564, HP0305, Cag δ , HyuA and Catalase (ORs between 0.91-99) (Table 3) compared to being male.

The influence of co-infection on Helicobacter pylori antibody responses

We then investigated the seroprevalence of co-infection in 1,735 individuals (aged 1-91 years, median= 31) that had a record of infection serostatus for nine additional pathogens. We found that in

1,679 (97%) *H.pylori* positive individuals there was a high burden of co-infection, particularly with Epstein-Barr Virus (EBV) and Kaposi's Sarcoma-associated herpesvirus (KSHV) (93%) (Figure 3.A.) followed by Herpes-simplex virus-2 (HSV-2) (67%), Human Papilloma Virus (HPV) (35%) and Hepatitis B Virus (HBV) (13%). The remaining four pathogens were <10% with Human T lymphotropic virus-1 (HTLV-1) having the lowest seroprevalence (~1%) (Figure 3.A.). Most individuals (~70%) were co-infected with at least four pathogens (Figure 3.B).

We then investigated the influence of co-infection on inter-individual variation in antibody response levels to the five virulent *H. pylori* antigens, CagA, VacA, GroEL, HcpC and HP1564, in *H.pylori* seropositive individuals using multivariable linear regression models adjusting for age, sex, sampling year and infection status. Of the infections tested (Figure 3. A), HIV co-infection resulted in significantly lowered antibody responses to CagA, HcpC, and HP1564 (OR= 0.55-0.93) (Table 4). HSV-2 co-infection was associated with moderately higher levels of CagA and VacA (OR= 1.05-1.16) but no other antibodies (Table 4). HPV co-infection was significantly associated with higher antibody levels (OR= 1.11-1.45) to VacA and GroEL antigens (Table 4). None of the other co-infections had significant effects on variation for any antibody response ($p>0.004$) (Table 4).

Discussion

Data on *Helicobacter pylori* antibody response patterns and their determinants are limited, with most studies having been conducted in Western and non-African populations, there is a paucity of data particularly from Africa. Here, we present the first population-based study to characterise *H. pylori* antibody response patterns to 14 antigens and their determinants in ~7000 individuals from an African population. The presence of antibodies representing host immune response is commonly used as diagnostic markers for the stage of infection [16] and for *H.pylori* they have been found to be associated with disease risk[8, 9]. In the GPC, prevalence estimates of *H. pylori* of ~94% are higher than previous findings in Uganda and more broadly in developing countries[17-21]. Here, we see a population with a high seroprevalence of >90% from childhood, much higher than previously observed in Uganda of 44%; a seroprevalence higher than in other African countries, with studies

reporting estimates in children ranging from 14% in Ghana to 73% in Kenya[11, 12, 17, 22]. We observed slightly higher seroprevalence in the highest age group compared to the lowest age groups ($p<0.05$), consistent with previous findings in other populations. In comparison to a previous study of German individuals[10] that assessed the presence of the 14 antigens tested here, we observed a 2-fold increase in seropositivity to *H. pylori* (95% in the GPC vs 48% in Germans). In *H. pylori* seropositive individuals, we observed >90% seropositivity to the following antibodies: CagA, HP1564, VacA and Cag δ , which was much higher than reported in previous studies. The highest difference in seroprevalence (2.7-fold) was observed for CagA (90% vs 33% Germans). For the following antigens: Cag δ , HP0231, HpaA, CagM and Catalase we also observed a >2-fold difference in seroprevalence with higher estimates in Ugandans compared to Germans. The lowest difference in seroprevalence was observed for HcpC, 1.17-fold higher in Ugandans compared to Germans. Another study in adults from high-risk gastric cancer areas of Latin America also reported lower antibody seroprevalences compared to our study, including for CagA (74%) and VacA (71%) despite an overall *H. pylori* seroprevalence of 85%[23]. Differences in seropositivity have also been reported in a low-income population in the U.S.A that had a higher *H. pylori* seropositivity 89% compared to the general US population (~30%), thought to be driven by lower socio-economic status[24]. They also observed higher seroprevalence in and higher in African Americans 79% compared to 69% in whites in addition to higher antibody seroprevalence for 12 out of the 14 antigens tested here, particularly for CagA, with a 2.6-fold increase in African Americans (68%) compared to white Americans (26%)[24]. This could be suggestive of higher seroprevalence in individuals with African ancestry. While seroprevalence estimates of CagA in Africa are scarce, the ubiquity of CagA in the GPC mirrors estimates in East Asian countries where the risk of gastric cancers due to *H. pylori* are higher than the rest of the world[3, 25]. CagA and VacA are the most well studied virulence factors of *H. pylori* and are essential for bacterial persistence in the stomach in addition to possessing oncogenic potential. CagA-host interaction induce a state of chronic inflammation which worsens over time and has been associated with an increased risk of gastric cancers, peptic ulcers, and other complications[26-28]. Studies that have evaluated antibody response levels to CagA and VacA report

high antibody levels are associated with gastric mucosal inflammation, the grade of histological gastritis, and gastric cancer risk[29, 30]. It is interesting to observe such high seropositivity and immunogenicity to the high-risk serotypes, CagA and VacA in the GPC compared to non-African populations. A recent study in individuals in Southeast USA also found significantly higher levels of antibodies to CagA and VacA in African Americans compared to whites[31] that was likely driven by differences in ancestry.

Differences in antibody responses compared to other populations could occur as a result of multiple factors particularly, host genetic and environmental variation. In the GPC, a high burden of co-infection exists, with most individuals having up to four infections (Figure 3), therefore we sought to investigate whether inter-individual variation in antibody responses to the five virulent antigens CagA, VacA, HP1564, HcpC and GroEL was influenced by co-infection with pathogens previously reported to have oncogenic potential[3]. Out of the infections tested, only HIV, HSV-2 and HPV (high risk genotypes 16 or 18) co-infection influenced antibody levels. We found that while HIV infection was associated with decreased antibody responses (OR=0.53-0.99), co-infection with HSV-2 or HPV were significantly associated with moderate increases in antibody responses (OR=1.05-1.45) (Table 4). Co-infections can cause an imbalance in host immune system, likely modulating shared inflammatory pathways and thus, resulting in antibody variation[32-35]. However, as effect sizes in this study are small, they only partially explain inter-individual differences in antibody patterns.

In summary, we characterised antibody response patterns to 14 *H. pylori* antigens in ~7,000 individuals from a rural Ugandan population cohort and identified factors associated with inter-individual variation in response. A major finding of this study is that *H. pylori* seropositivity is ubiquitous from childhood (94%), and higher than previous reports in Uganda and other countries which could be due to lower-socioeconomic status in this cohort compared to urban areas. We also found that antigen specific seropositivity to the 14 antigens tested here, particularly for CagA, are higher than for non-African populations. Inter-

individual variation in antibody responses was partly explained by HIV, HSV-2 and HPV co-infections, suggesting other factors not examined here such as host genetics might be important. These insights are useful to better stratify individuals at risk of developing adverse outcomes following infection, as this population sustains such high levels of *H. pylori*, further investigation will be essential to inform appropriate therapeutic interventions to prevent disease in those at risk. Future studies would need to assess the relationship between antibody responses and clinical outcomes, and also investigate the relationship between host genetic variation and antibody variation to fully understand disease risk and population specific differences that are not explained by environmental variation.

Acknowledgements

We thank all study participants who contributed to this study and acknowledge the support of the MRC/UVRI & LSHTM Uganda Research Unit

Funding

The GPC is jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement. Additional financial support for accessing serological samples was provided by a Wellcome Trust Clinical Training Fellowship awarded to Dr Katie Wakeham for work on the Kaposi's sarcoma associated herpesvirus (Grant number: 090132).

Author Contributions

N.S, R.N. ,T.W. & M.L.H. designed the study. N.S & R.N wrote the manuscript. J.B & T.W performed phenotype assay development and validation. W.T.J, carried out curation of the cohort data and managed the database. N.S, A.H & N.O carried out all statistical analyses and data visualisation. N.S, R.N. & J.B. interpreted the results. G.A was the programme leader for the GPC. All authors commented on the interpretation of the results, reviewed and approved the final manuscript.

301

302 **Conflict of interest**

303 None

304

305

306 **References**

307

308 1. Weyermann M, Rothenbacher D, Brenner H. Acquisition of *Helicobacter pylori* infection in
309 early childhood: independent contributions of infected mothers, fathers, and siblings. *Am J*
310 *Gastroenterol.* 2009;104(1):182-9. Epub 2008/12/23. doi: 10.1038/ajg.2008.61. PubMed PMID:
311 19098867.

312 2. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global
313 Prevalence of *Helicobacter pylori* Infection: Systematic Review and Meta-Analysis.
314 *Gastroenterology.* 2017;153(2):420-9. Epub 2017/05/01. doi: 10.1053/j.gastro.2017.04.022. PubMed
315 PMID: 28456631.

316 3. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable
317 to infections in 2018: a worldwide incidence analysis. *Lancet Glob Health.* 2020;8(2):e180-e90. Epub
318 2019/12/22. doi: 10.1016/S2214-109X(19)30488-7. PubMed PMID: 31862245.

319 4. Parkin DM, Hammerl L, Ferlay J, Kantelhardt EJ. Cancer in Africa 2018: The role of
320 infections. *Int J Cancer.* 2019. Epub 2019/06/30. doi: 10.1002/ijc.32538. PubMed PMID: 31254479.

321 5. M. Galukande M, A. Luwaga, J. Jombwe, J. Fualal, J. Kigula-Mugamba, A. Kanyike, et al.
322 Gastric Cancer Diagnosis and Treatment guidelines 2008: Uganda Cancer Working Group. *East and*
323 *Central African Journal of Surgery.* 2008;13(2):142-9.

324 6. Herrero R, Park JY, Forman D. The fight against gastric cancer - the IARC Working Group
325 report. *Best Pract Res Clin Gastroenterol.* 2014;28(6):1107-14. Epub 2014/12/03. doi:
326 10.1016/j.bpg.2014.10.003. PubMed PMID: 25439075.

327 7. van Amsterdam K, van Vliet AH, Kusters JG, van der Ende A. Of microbe and man:
328 determinants of *Helicobacter pylori*-related diseases. *FEMS Microbiol Rev.* 2006;30(1):131-56. Epub
329 2006/01/28. doi: 10.1111/j.1574-6976.2005.00006.x. PubMed PMID: 16438683.

- 330 8. Gao L, Michel A, Weck MN, Arndt V, Pawlita M, Brenner H. Helicobacter pylori infection
331 and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology.
332 Cancer Res. 2009;69(15):6164-70. Epub 2009/07/16. doi: 10.1158/0008-5472.CAN-09-0596.
333 PubMed PMID: 19602590.
- 334 9. Gao L, Weck MN, Michel A, Pawlita M, Brenner H. Association between chronic atrophic
335 gastritis and serum antibodies to 15 Helicobacter pylori proteins measured by multiplex serology.
336 Cancer Res. 2009;69(7):2973-80. Epub 2009/03/26. doi: 10.1158/0008-5472.CAN-08-3477. PubMed
337 PMID: 19318564.
- 338 10. Michel A, Pawlita M, Boeing H, Gissmann L, Waterboer T. Helicobacter pylori antibody
339 patterns in Germany: a cross-sectional population study. Gut Pathog. 2014;6:10. Epub 2014/05/02.
340 doi: 10.1186/1757-4749-6-10. PubMed PMID: 24782915; PubMed Central PMCID:
341 PMCPMC4004453.
- 342 11. Smith S, Fowora M, Pellicano R. Infections with Helicobacter pylori and challenges
343 encountered in Africa. World J Gastroenterol. 2019;25(25):3183-95. Epub 2019/07/25. doi:
344 10.3748/wjg.v25.i25.3183. PubMed PMID: 31333310; PubMed Central PMCID: PMCPMC6626727.
- 345 12. Zamani M, Ebrahimitabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, et
346 al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection.
347 Alimentary Pharmacology & Therapeutics. 2018;47(7):868-76. doi: 10.1111/apt.14561.
- 348 13. Asiki G, Murphy G, Nakiyingi-Miiró J, Seeley J, Nsubuga RN, Karabarinde A, et al. The
349 general population cohort in rural south-western Uganda: a platform for communicable and non-
350 communicable disease studies. Int J Epidemiol. 2013;42(1):129-41. Epub 2013/02/01. doi:
351 10.1093/ije/dys234. PubMed PMID: 23364209; PubMed Central PMCID: PMCPMC3600628.
- 352 14. Nunn AJ, Mulder DW, Kamali A, Ruberantwari A, Kengeya-Kayondo J-F, Whitworth J.
353 Mortality associated with HIV-1 infection over five years in a rural Ugandan population: cohort
354 study. BMJ. 1997;315:767-71. doi: 10.1136/bmj.315.7111.767.
- 355 15. Michel A, Waterboer T, Kist M, Pawlita M. Helicobacter pylori multiplex serology.
356 Helicobacter. 2009;14(6):525-35. Epub 2009/11/06. doi: 10.1111/j.1523-5378.2009.00723.x. PubMed
357 PMID: 19889070.

358 16. Morrison BJ, Labo N, Miley WJ, Whitby D. Serodiagnosis for tumor viruses. *Seminars in*
359 *oncology*. 2015;42:191-206. doi: 10.1053/j.seminoncol.2014.12.024. PubMed PMID: 25843726.

360 17. Aitila P, Mutyaba M, Okeny S, Ndawula Kasule M, Kasule R, Ssedyabane F, et al.
361 Prevalence and Risk Factors of *Helicobacter pylori* Infection among Children Aged 1 to 15 Years at
362 Holy Innocents Children's Hospital, Mbarara, South Western Uganda. *J Trop Med*.
363 2019;2019:9303072. Epub 2019/04/16. doi: 10.1155/2019/9303072. PubMed PMID: 30984271;
364 PubMed Central PMCID: PMC6431523.

365 18. Hestvik E, Tylleskar T, Kaddu-Mulindwa DH, Ndeezi G, Grahnquist L, Olafsdottir E, et al.
366 *Helicobacter pylori* in apparently healthy children aged 0-12 years in urban Kampala, Uganda: a
367 community-based cross sectional survey. *BMC Gastroenterol*. 2010;10:62. Epub 2010/06/18. doi:
368 10.1186/1471-230X-10-62. PubMed PMID: 20553588; PubMed Central PMCID: PMC2901381.

369 19. Ankarklev J, Hestvik E, Lebbad M, Lindh J, Kaddu-Mulindwa DH, Andersson JO, et al.
370 Common coinfections of *Giardia intestinalis* and *Helicobacter pylori* in non-symptomatic Ugandan
371 children. *PLoS Negl Trop Dis*. 2012;6(8):e1780. Epub 2012/09/07. doi:
372 10.1371/journal.pntd.0001780. PubMed PMID: 22953010; PubMed Central PMCID:
373 PMC3429385.

374 20. Newton R, Ziegler JL, Casabonne D, Carpenter L, Gold BD, Owens M, et al. *Helicobacter*
375 *pylori* and cancer among adults in Uganda. *Infect Agent Cancer*. 2006;1:5. Epub 2006/12/08. doi:
376 10.1186/1750-9378-1-5. PubMed PMID: 17150134; PubMed Central PMCID: PMC1660530.

377 21. Baingana RK, Kiboko Enyaru J, Davidsson L. *Helicobacter pylori* infection in pregnant
378 women in four districts of Uganda: role of geographic location, education and water sources. *BMC*
379 *Public Health*. 2014;14:915. Epub 2014/09/06. doi: 10.1186/1471-2458-14-915. PubMed PMID:
380 25190150; PubMed Central PMCID: PMC4164757.

381 22. Awuku YA, Simpong DL, Alhassan IK, Tuoyire DA, Afaa T, Adu P. Prevalence of
382 *helicobacter pylori* infection among children living in a rural setting in Sub-Saharan Africa. *BMC*
383 *Public Health*. 2017;17(1):360. Epub 2017/04/26. doi: 10.1186/s12889-017-4274-z. PubMed PMID:
384 28438158; PubMed Central PMCID: PMC5404296.

23. Camargo MC, Beltran M, Conde-Glez CJ, Harris PR, Michel A, Waterboer T, et al. Serological response to *Helicobacter pylori* infection among Latin American populations with contrasting risks of gastric cancer. *Int J Cancer*. 2015;137(12):3000-5. Epub 2015/07/17. doi: 10.1002/ijc.29678. PubMed PMID: 26178251; PubMed Central PMCID: PMC4817269.
24. Epplein M, Signorello LB, Zheng W, Peek RM, Jr., Michel A, Williams SM, et al. Race, African ancestry, and *Helicobacter pylori* infection in a low-income United States population. *Cancer Epidemiol Biomarkers Prev*. 2011;20(5):826-34. Epub 2011/03/02. doi: 10.1158/1055-9965.EPI-10-1258. PubMed PMID: 21357376; PubMed Central PMCID: PMC3089670.
25. Hatakeyama M. *Helicobacter pylori* CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. *Cell Host Microbe*. 2014;15(3):306-16. Epub 2014/03/19. doi: 10.1016/j.chom.2014.02.008. PubMed PMID: 24629337.
26. Park JY, Forman D, Waskito LA, Yamaoka Y, Crabtree JE. Epidemiology of *Helicobacter pylori* and CagA-Positive Infections and Global Variations in Gastric Cancer. *Toxins (Basel)*. 2018;10(4). Epub 2018/04/20. doi: 10.3390/toxins10040163. PubMed PMID: 29671784; PubMed Central PMCID: PMC5923329.
27. Jones KR, Whitmire JM, Merrell DS. A Tale of Two Toxins: *Helicobacter Pylori* CagA and VacA Modulate Host Pathways that Impact Disease. *Front Microbiol*. 2010;1:115. Epub 2010/01/01. doi: 10.3389/fmicb.2010.00115. PubMed PMID: 21687723; PubMed Central PMCID: PMC3109773.
28. Gwack J, Shin A, Kim CS, Ko KP, Kim Y, Jun JK, et al. CagA-producing *Helicobacter pylori* and increased risk of gastric cancer: a nested case-control study in Korea. *Br J Cancer*. 2006;95(5):639-41. Epub 2006/08/16. doi: 10.1038/sj.bjc.6603309. PubMed PMID: 16909137; PubMed Central PMCID: PMC2360680.
29. Shiota S, Murakami K, Okimoto T, Kodama M, Yamaoka Y. Serum *Helicobacter pylori* CagA antibody titer as a useful marker for advanced inflammation in the stomach in Japan. *J Gastroenterol Hepatol*. 2014;29(1):67-73. Epub 2013/09/17. doi: 10.1111/jgh.12359. PubMed PMID: 24033876; PubMed Central PMCID: PMC3870047.

30. Yoshida T, Kato J, Inoue I, Yoshimura N, Deguchi H, Mukoubayashi C, et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. *Int J Cancer*. 2014;134(6):1445-57. Epub 2013/09/07. doi: 10.1002/ijc.28470. PubMed PMID: 24009139.
31. Butt J, Blot WJ, Shrubsole MJ, Waterboer T, Pawlita M, Epplein M. Differences in antibody levels to H. pylori virulence factors VacA and CagA among African Americans and whites in the Southeast USA. *Cancer Causes Control*. 2020. Epub 2020/03/31. doi: 10.1007/s10552-020-01295-z. PubMed PMID: 32222845.
32. Del Moral-Hernandez O, Castanon-Sanchez CA, Reyes-Navarrete S, Martinez-Carrillo DN, Betancourt-Linares R, Jimenez-Wences H, et al. Multiple infections by EBV, HCMV and Helicobacter pylori are highly frequent in patients with chronic gastritis and gastric cancer from Southwest Mexico: An observational study. *Medicine (Baltimore)*. 2019;98(3):e14124. Epub 2019/01/18. doi: 10.1097/MD.00000000000014124. PubMed PMID: 30653141; PubMed Central PMCID: PMC6370051.
33. Vedham V, Divi RL, Starks VL, Verma M. Multiple infections and cancer: implications in epidemiology. *Technol Cancer Res Treat*. 2014;13(2):177-94. Epub 2013/08/08. doi: 10.7785/tcrt.2012.500366. PubMed PMID: 23919392.
34. Du Y, Agnew A, Ye XP, Robinson PA, Forman D, Crabtree JE. Helicobacter pylori and Schistosoma japonicum co-infection in a Chinese population: helminth infection alters humoral responses to H. pylori and serum pepsinogen I/II ratio. *Microbes Infect*. 2006;8(1):52-60. Epub 2005/11/02. doi: 10.1016/j.micinf.2005.05.017. PubMed PMID: 16260169.
35. Mbulaiteye SM, Gold BD, Pfeiffer RM, Brubaker GR, Shao J, Biggar RJ, et al. H. pylori-infection and antibody immune response in a rural Tanzanian population. *Infect Agent Cancer*. 2006;1:3. Epub 2006/12/08. doi: 10.1186/1750-9378-1-3. PubMed PMID: 17150132; PubMed Central PMCID: PMC636024.

Figure Legends

Figure 1. *H. pylori* seropositivity by gender and age. Star indicates statistically significant difference between genders in age 25-44, $p=0.03$ (Fisher's exact test). Horizontal brackets indicate statistically significant differences between the youngest (0-14) and oldest (45+) age groups for both genders: Males: $p=0.02$, females: $p=0.01$ (Wilcoxon two sample signed rank sum test).

Figure. 2. Distribution of antibody responses ($\log_{10}$ MFI) in *H. pylori* positive and antigen positive individuals. Horizontal lines denote median and vertical lines denote interquartile range (IQR).

Figure 3. A. Seroprevalence of co-infection in *H. pylori* seropositive individuals (n=1679). EBV: Epstein Barr Virus, KSHV: Kaposi's Sarcoma-associated Herpesvirus, HSV-2: Herpes Simplex Virus-2, HBV: Hepatitis B virus, HPV: Human papilloma virus, MCV: Merkel Cell polyoma virus, HIV: Human Immunodeficiency virus, HCV: Hepatitis C virus and HTLV-1: Human T-cell Lymphotropic virus. **B. Burden of infection.** Infection count represents the number of infections the individuals tested positive for.

466 Tables

467

Table.1 Characteristics of samples in the GPC (n=7211)

Variable	Category	N	%	HP+(%)
Sex	Female	3689	51	94
	Male	3522	49	96
Age [Years]	0-14	3129	43	93
	15-24	1509	21	98
	25-44	1307	18	96
	45+	1266	18	95
<i>H. pylori</i> Status	Positive	6834	95	100
	Negative	377	5	-
Census Year	1992	1920	27	94
	2000	2342	33	96
	2008	2949	41	94

^a*H. pylori* seropositivity determined as antibody reactivity with at least 4 antigens

*Fisher's exact test, comparison of Hp- and Hp+ sera.

468

Table.2 Seroprevalence of antibodies to *H. pylori* antigens by HP serostatus

Seroprevalence (%)						
Antigen	Name	Cut-off [MFI]	All (n=7211)	Hp+ ^a (n=6834)	Hp- (n=377)	P*
HP0547	CagA	2592	90	100	28	<0.0001
HP0010	GroEL	100	62	69	6	<0.0001
HP1564	HP1564	188	83	93	18	<0.0001
HP0887	VacA	541	89	99	22	<0.0001
HP0305	HP0305	100	45	51	2	<0.0001
HP0410	HpaA	100	56	63	7	<0.0001
HP0522	Cagδ	500	90	99	46	<0.0001
HP0695	HyuA	191	48	54	7	<0.0001
HP0537	CagM	158.75	65	72	20	<0.0001
HP0875	Catalase	455	64	71	22	<0.0001
HP0231	HP0231	100	65	73	7	<0.0001
HP1098	HcpC	100	40	44	0	<0.0001
HP0243	NapA	100	43	49	6	<0.0001
HP0073	UreA	340	50	57	14	<0.0001

469

Table 3. Predictors of antibody response levels to <i>H. pylori</i> antigens in seropositive individuals						
Variable	Age Group: Ref =0-14 years			Sex: Ref=Male	Census Year: Ref=1990	
Antigen	15-24	25-44	45+	Female	2000	2008
CagA						
OR (95% C.I)	0.98 (0.96 - 0.99)	0.96 (0.95 - 0.98)	0.91 (0.90 - 0.93)	1.00 (0.99 - 1.01)	1.03 (1.01 - 1.04)	1.04 (1.03 - 1.06)
p-value	0.002	<0.001	<0.001	0.540	<0.001	<0.001
GroEL						
OR (95% C.I)	1.08 (1.04 - 1.11)	1.06 (1.03 - 1.1)	1.10 (1.06 - 1.14)	0.98 (0.96 - 1.01)	1.04 (1.01 - 1.07)	1.11 (1.07 - 1.14)
p-value	<0.001	0.001	<0.001	0.153	0.019	<0.001
HP1564						
OR (95% C.I)	0.95 (0.92 - 0.97)	0.89 (0.87 - 0.92)	0.86 (0.84 - 0.89)	0.93 (0.91 - 0.95)	1.02 (0.99 - 1.05)	0.99 (0.97 - 1.02)
p-value	<0.001	<0.001	<0.001	<0.001	0.146	0.699
VacA						
OR (95% C.I)	1.01 (0.99 - 1.03)	0.99 (0.97 - 1.01)	0.97 (0.94 - 0.99)	0.98 (0.97 - 1.00)	1.03 (1.01 - 1.05)	1 (0.98 - 1.02)
p-value	0.224	0.399	0.002	0.019	0.004	0.701
HP0305						
OR (95% C.I)	0.94 (0.91 - 0.98)	0.94 (0.90 - 0.98)	0.95 (0.91 - 1.00)	0.94 (0.91 - 0.97)	1.01 (0.97 - 1.05)	1.05 (1.01 - 1.09)
p-value	0.004	0.004	0.041	<0.001	0.523	0.013
HpaA						
OR (95% C.I)	1.03 (0.99 - 1.06)	0.98 (0.94 - 1.02)	1.02 (0.98 - 1.06)	0.97 (0.95 - 1.00)	1.04 (1.00 - 1.07)	1.03 (0.99 - 1.06)
p-value	0.106	0.290	0.257	0.023	0.026	0.102
CagD						
OR (95% C.I)	1.03 (1.01 - 1.05)	1.04 (1.02 - 1.06)	1.03 (1.01 - 1.05)	0.95 (0.93 - 0.96)	1.01 (1.00 - 1.03)	0.98 (0.97 - 1.00)
p-value	0.002	0.001	0.005	<0.001	0.143	0.112
HyuA						
OR (95% C.I)	1.02 (0.98 - 1.06)	1.12 (1.07 - 1.16)	1.15 (1.10 - 1.19)	0.96 (0.93 - 0.99)	1.01 (0.97 - 1.05)	1.02 (0.98 - 1.06)
p-value	0.254	<0.001	<0.001	0.003	0.613	0.325
CagM						
OR (95% C.I)	1.01 (0.98 - 1.04)	0.99 (0.96 - 1.03)	0.99 (0.96 - 1.03)	0.98 (0.96 - 1.01)	1.01 (0.98 - 1.04)	1.03 (1.00 - 1.06)
p-value	0.408	0.746	0.686	0.151	0.475	0.022
Catalase						
OR (95% C.I)	0.98 (0.96 - 1.01)	0.98 (0.95 - 1.01)	0.99 (0.96 - 1.02)	0.97 (0.95 - 0.99)	1.01 (0.99 - 1.04)	1.03 (1.01 - 1.06)
p-value	0.169	0.173	0.485	0.001	0.319	0.008
HP0231						
OR (95% C.I)	0.96 (0.93 - 1.00)	0.93 (0.89 - 0.97)	1.00 (0.96 - 1.04)	0.97 (0.94 - 1.00)	1.01 (0.98 - 1.05)	1.06 (1.03 - 1.1)
p-value	0.028	0.001	0.838	0.023	0.515	<0.001
HcpC						

OR (95% C.I)	1.00 (0.95 - 1.05)	1.06 (1.00 - 1.13)	1.13 (1.07 - 1.20)	0.96 (0.92 - 1.00)	1.03 (0.98 - 1.09)	1.04 (0.99 - 1.09)
p-value	0.924	0.049	<0.001	0.044	0.219	0.137
NapA						
OR (95% C.I)	1.13 (1.07 - 1.20)	1.14 (1.07 - 1.21)	1.13 (1.06 - 1.20)	1.00 (0.95 - 1.04)	0.98 (0.92 - 1.03)	1.00 (0.95 - 1.06)
p-value	<0.001	<0.001	<0.001	0.813	0.389	0.879
UreA						
OR (95% C.I)	1.01 (0.98 - 1.04)	1.02 (0.99 - 1.05)	1.07 (1.04 - 1.10)	0.97 (0.95 - 0.99)	1.00 (0.97 - 1.03)	1.02 (0.99 - 1.05)
p-value	0.395	0.159	<0.001	0.012	0.864	0.120

470

471

Table 4. The influence of co-infection on antibody response levels to virulent <i>H. pylori</i> antigens (N=1679)										
Antigen	CagA		VacA		GroEL		HcpC		HP1564	
Variable	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Age	0.999 (0.997 - 1)	0.007	0.998 (0.997 - 0.999)	0.001	1.001 (0.998 - 1.004)	0.330	0.996 (0.993 - 0.999)	0.003	0.995 (0.992 - 0.997)	<0.001
Sex: Ref=Male										
Female	0.98 (0.94 - 1.02)	0.282	0.98 (0.94 - 1.02)	0.414	1.00 (0.9 - 1.1)	0.923	0.90 (0.81 - 1)	0.050	0.84 (0.77 - 0.91)	<0.001
Year: Ref=1992										
2000	1.03 (0.96 - 1.12)	0.389	1.07 (0.98 - 1.16)	0.111	1.2 (0.98 - 1.48)	0.083	1.00 (0.82 - 1.23)	0.980	1.06 (0.9 - 1.25)	0.459
2008	1.08 (1.01 - 1.16)	0.034	1.05 (0.97 - 1.13)	0.239	1.47 (1.21 - 1.78)	<0.001	1.06 (0.88 - 1.28)	0.535	1.03 (0.89 - 1.19)	0.707
HIV: Ref=Negative										
Positive	0.86 (0.8 - 0.93)	<0.001	0.90 (0.82 - 0.97)	0.010	0.94 (0.76 - 1.16)	0.539	0.68 (0.55 - 0.83)	<0.001	0.75 (0.64 - 0.88)	0.001
HSV-2: Ref=Negative										
Positive	1.10 (1.05 - 1.15)	<0.001	1.11 (1.05 - 1.16)	<0.001	1.18 (1.04 - 1.34)	0.011	1.02 (0.9 - 1.15)	0.782	1.06 (0.96 - 1.17)	0.246
HPV: Ref=Negative										
Positive	1.04 (1 - 1.09)	0.032	1.16 (1.11 - 1.21)	<0.001	1.30 (1.16 - 1.45)	<0.001	1.07 (0.96 - 1.19)	0.231	1.12 (1.03 - 1.22)	0.007
EBV: Ref=Negative										
Positive	0.94 (0.87 - 1.01)	0.099	1.09 (1 - 1.18)	0.050	0.87 (0.7 - 1.08)	0.208	1.08 (0.88 - 1.34)	0.454	0.96 (0.81 - 1.13)	0.608
KSHV: Ref=Negative										
Positive	1.05 (0.98 - 1.12)	0.189	1.09 (1.01 - 1.18)	0.030	1.08 (0.87 - 1.34)	0.492	0.89 (0.73 - 1.08)	0.280	1.02 (0.87 - 1.19)	0.847

	1.13)		1.19)		1.32)		1.1)		1.19)	
HBV: Ref=Negative										
Positive	1.00 (0.93 - 1.07)	0.99 6	0.97 (0.9 - 1.04)	0.38 2	1.19 (0.98 - 1.44)	0.081	1.08 (0.89 - 1.3)	0.42 7	1.16 (1 - 1.34)	0.04 8
MCV: Ref=Negative										
Positive	0.97 (0.91 - 1.03)	0.34 1	1.02 (0.96 - 1.09)	0.51 8	1.19 (1 - 1.41)	0.046	1.04 (0.88 - 1.23)	0.66 4	1.03 (0.91 - 1.18)	0.61 8
HCV: Ref=Negative										
Positive	1.00 (0.92 - 1.09)	0.98 4	0.99 (0.9 - 1.09)	0.90 5	0.94 (0.74 - 1.2)	0.626	0.98 (0.77 - 1.25)	0.87 9	0.94 (0.78 - 1.14)	0.55 2
HTLV-1: Ref=Negative										
Positive	0.83 (0.66 - 1.03)	0.09 3	1.28 (1.01 - 1.62)	0.04 3	0.93 (0.5 - 1.7)	0.807	0.80 (0.44 - 1.46)	0.47 2	0.76 (0.48 - 1.22)	0.26 0

472

A **B**